These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 11877752

  • 1. Biokinetics of yttrium-90--labeled huBrE-3 monoclonal antibody.
    Johnson TK, Cole W, Quaife RA, Lear JL, Ceriani RL, Jones RB, Cagnoni PJ.
    Cancer; 2002 Feb 15; 94(4 Suppl):1240-8. PubMed ID: 11877752
    [Abstract] [Full Text] [Related]

  • 2. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer.
    Kramer EL, Liebes L, Wasserheit C, Noz ME, Blank EW, Zabalegui A, Melamed J, Furmanski P, Peterson JA, Ceriani RL.
    Clin Cancer Res; 1998 Jul 15; 4(7):1679-88. PubMed ID: 9676842
    [Abstract] [Full Text] [Related]

  • 3. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
    Carrasquillo JA, White JD, Paik CH, Raubitschek A, Le N, Rotman M, Brechbiel MW, Gansow OA, Top LE, Perentesis P, Reynolds JC, Nelson DL, Waldmann TA.
    J Nucl Med; 1999 Feb 15; 40(2):268-76. PubMed ID: 10025834
    [Abstract] [Full Text] [Related]

  • 4. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
    Wong JY, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, Wilczynski S, Wu AM, Yazaki PJ, Shively JE, Leong L, Raubitschek AA.
    Cancer Biother Radiopharm; 2006 Apr 15; 21(2):88-100. PubMed ID: 16706629
    [Abstract] [Full Text] [Related]

  • 5. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 15; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 6. Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model.
    Nemecek ER, Hamlin DK, Fisher DR, Krohn KA, Pagel JM, Appelbaum FR, Press OW, Matthews DC.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):787-94. PubMed ID: 15701869
    [Abstract] [Full Text] [Related]

  • 7. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY, Chu DZ, Yamauchi D, Odom-Maryon TL, Williams LE, Liu A, Esteban JM, Wu AM, Primus FJ, Beatty JD, Shively JE, Raubitschek AA.
    J Nucl Med; 1998 Dec 15; 39(12):2097-104. PubMed ID: 9867150
    [Abstract] [Full Text] [Related]

  • 8. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM.
    J Nucl Med; 2003 Jan 15; 44(1):77-84. PubMed ID: 12515879
    [Abstract] [Full Text] [Related]

  • 9. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ, Grant EJ, Kasi L, Rosenblum MG, Zhang HZ, Katz RL, Rieger PT, LeBherz D, South M, Greiner JW, Schlom J, Podoloff DA, Murray JL.
    Clin Cancer Res; 1997 Sep 15; 3(9):1547-55. PubMed ID: 9815842
    [Abstract] [Full Text] [Related]

  • 10. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA.
    J Nucl Med; 2003 Mar 15; 44(3):465-74. PubMed ID: 12621016
    [Abstract] [Full Text] [Related]

  • 11. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
    Iznaga-Escobar N, Torres LA, Morales A, Ramos M, Alvarez I, Pérez N, Fraxedas R, Rodríguez O, Rodríguez N, Pérez R, Lage A, Stabin MG.
    J Nucl Med; 1998 Jan 15; 39(1):15-23. PubMed ID: 9443731
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM.
    J Nucl Med; 2003 Dec 15; 44(12):2000-18. PubMed ID: 14660727
    [Abstract] [Full Text] [Related]

  • 15. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.
    Clin Cancer Res; 1999 May 15; 5(5):953-61. PubMed ID: 10353726
    [Abstract] [Full Text] [Related]

  • 16. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
    Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL.
    Clin Cancer Res; 2005 Aug 15; 11(16):5920-7. PubMed ID: 16115934
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
    DeNardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL, DeNardo GL.
    J Nucl Med; 1997 Aug 15; 38(8):1180-5. PubMed ID: 9255145
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
    Kobayashi H, Wu C, Kim MK, Paik CH, Carrasquillo JA, Brechbiel MW.
    Bioconjug Chem; 1999 Aug 15; 10(1):103-11. PubMed ID: 9893971
    [Abstract] [Full Text] [Related]

  • 20. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.
    Wong JY, Williams LE, Yamauchi DM, Odom-Maryon T, Esteban JM, Neumaier M, Wu AM, Johnson DK, Primus FJ, Shively JE.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5929s-5934s. PubMed ID: 7493373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.